{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:37:49Z","timestamp":1771933069358,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T00:00:00Z","timestamp":1190592000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>A<jats:sc>bstract<\/jats:sc><\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Effective management of ocular hypertension requires patients to be persistent with their treatment regimen. We evaluated patients' persistency with hypotensive eyedrops commonly used to treat glaucoma and ocular hypertension.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This large, population\u2010based, retrospective, cohort study used pharmacy claims data for concessional patients from the Australian Pharmaceutical Benefits Scheme (July 1999\u2013June 2005). Resupply rates for prostaglandins, beta\u2010blockers, alpha\u2010agonists and carbonic anhydrase inhibitors were analysed using life tables and Cox regression. Two populations, based on patients' supply histories, were examined: (i) \u2018new to this eyedrop\u2019\u2013 patients who had used other hypotensive eyedrops before (presumably, previously diagnosed with glaucoma or ocular hypertension); and (ii) \u2018new to any eyedrop\u2019\u2013 patients who were using their first hypotensive eyedrop (presumably, newly diagnosed with glaucoma or ocular hypertension).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Data were obtained for 14\u2003359\u2003618 supplies of commonly used hypotensive eyedrops to 357\u2003099 concessional patients. For both populations, resupply rates were highest for prostaglandins or the dorzolamide\u2010timolol combination eyedrops, compared with beta\u2010blockers, alpha\u2010agonists or carbonic anhydrase inhibitors. Among the prostaglandins, there was no significant difference in the risk of ceasing supply between latanoprost and bimatoprost, but the risk was significantly higher for travoprost.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Based on resupply rates from a national pharmacy claims database, patients supplied with ocular hypotensive eyedrops were most persistent with prostaglandin (bimatoprost, latanoprost and travoprost) and dorzolamide\u2010timolol combination eyedrops. Among the prostaglandins, persistency was highest with, and similar between, bimatoprost and latanoprost. Persistency should be taken into account when selecting the most appropriate eyedrop to treat glaucoma and ocular hypertension.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2007.01564.x","type":"journal-article","created":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T08:42:26Z","timestamp":1190623346000},"page":"602-611","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Persistency rates for prostaglandin and other hypotensive eyedrops: population\u2010based study using pharmacy claims data"],"prefix":"10.1111","volume":"35","author":[{"given":"Julian L","family":"Rait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Adena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"449","article-title":"Estimating medication persistency using administrative claims data","volume":"11","author":"Sikka R","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.10.034"},{"key":"e_1_2_6_4_2","first-page":"S271","article-title":"Discontinuation rates of topical glaucoma medications in a managed care population","volume":"8","author":"Shaya FT","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_5_2","first-page":"S262","article-title":"Rates of discontinuation and change of glaucoma therapy in a managed care setting","volume":"8","author":"Spooner JJ","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.035"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000156139.05323.26"},{"key":"e_1_2_6_8_2","first-page":"S255","article-title":"Population\u2010based persistency rates for topical glaucoma medications measured with pharmacy claims data","volume":"8","author":"Dasgupta S","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80074-7"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037713"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.10.035"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.09.011"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2006.01196.x"},{"key":"e_1_2_6_14_2","unstructured":"Centrelink.A Guide to Centrelink Concession Cards. Accessed November 2005. Available from:http:\/\/www.centrelink.gov.au\/internet\/internet.nsf\/publications\/co153.htm"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.04.051"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/112067210501500507","article-title":"Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 2 years","volume":"15","author":"Rouland JF","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.01.042"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2006.01237.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71282-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74225-4"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80027-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200002000-00008"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.026"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2007.01564.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2007.01564.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:15:22Z","timestamp":1696922122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2007.01564.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1442-9071.2007.01564.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2007.01564.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"2007-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}